Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT00935090 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

StatusActive, Not Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion moved earlier from May 2027 to Apr 4, 2024
    • Enrollment closed, study ongoing
    • Study completion moved earlier from May 2028 to Apr 4, 2027
    • Site details revised
    v19
  2. Phase: Not applicable to Not specified
    • Primary completion date: May 2026 to May 2027
    • Enrollment target: 80 to not stated
    • Study completion date: May 2027 to May 2028
    v18
  3. Trial status: Suspended to Recruiting
    • Primary completion date: Jan 2024 to May 2026
    • Study completion date: Jan 2024 to May 2027
    • Site details revised
    v17
  4. Trial status: Recruiting to Suspended Sponsor's reason: The Investigator is negotiating with other company to use FLT PET
    • Primary completion date: Feb 9, 2023 to Jan 2024
    • Study completion date: Dec 2023 to Jan 2024
    • Site details revised
    v16
  5. Primary completion date: Dec 2021 to Feb 9, 2023
    • Study completion date: Dec 2021 to Dec 2023
    • Site contact updated
    v15
Show 13 earlier versionsHide 13 earlier versions
  1. Primary and study completion dates: Apr 2021 to Dec 2021v14
  2. Primary and study completion dates: Sep 2018 to Apr 2021v13
  3. Site contact updatedv12
  4. Phase: Phase 1 to Not applicable
    • Site contact updated
    v11
  5. Primary completion date: Jun 2015 to Sep 2018
    • Study completion date: Sep 2018
    v10
  6. Primary completion date: Dec 2013 to Jun 2015
    • Site contact updated
    v9
  7. Enrollment target: 20 to 80v8 Show 6 more changesShow less
    • Primary endpoints revised (2)
    • Study sites: 2 to 1
    • Primary completion date: Jun 2013 to Dec 2013
    • Interventions: 3'-deoxy-3'-[18F]fluorothymidine (Other) to 3'-deoxy-3'-[18F]fluorothymidine (Device)
    • Secondary endpoints: details revised at 1 of 1 entry
    • Study arms: 0 to 1
  8. Enrollment target: 80 to 20
    • Site contacts updated at 1 of 2 sites
    v7
  9. 4 versions Re-verified since Feb 20, 2010, no change to tracked fieldsv3-v6
  10. Trial status: Not Yet Recruiting to Recruiting
    • Start date: Jun 2009 to Sep 2009
    • Study sites: 0 to 2
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Barbara Ann Karmanos Cancer Institute
24 trials monitored
See 3 trials at risk
Leukemia
2,948 trials monitored
See 180 trials at risk
Non-Hodgkin Lymphoma
2,013 trials monitored
See 115 trials at risk
Acute Myeloid Leukemia (AML)
1,269 trials monitored
See 74 trials at risk
and 12 more diseases
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Trial Details
NCT Number NCT00935090
Lead Sponsor Barbara Ann Karmanos Cancer Institute
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms +1 more
Related terms Blast Crisis, Burkitt Lymphoma, Central Nervous System Neoplasms, Congenital Abnormalities, Hodgkin Disease, Immunoblastic Lymphadenopathy, Immunoglobulin Light-chain Amyloidosis, Intraocular Lymphoma, Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Hairy Cell, Leukemia, Large Granular Lymphocytic, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Mast-Cell, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Acute, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myelomonocytic, Chronic, Leukemia, Neutrophilic, Chronic, Leukemia, Prolymphocytic, Lymphoma, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Extranodal NK-T-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Mantle-Cell, Lymphoma, Non-Hodgkin, Lymphoma, T-Cell, Cutaneous, Lymphoproliferative Disorders, Multiple Myeloma, Mycosis Fungoides, Myelodysplastic Syndromes, Myelodysplastic-Myeloproliferative Diseases, Myeloproliferative Disorders, Neoplasms, Plasma Cell, Pdgfra-Associated Chronic Eosinophilic Leukemia, Polycythemia Vera, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis, Sezary Syndrome, Thrombocythemia, Essential, Waldenstrom Macroglobulinemia
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov